Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 7/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769551 | 0.93 | GAA (0.51) | KAT6AGAAAREGFRERBB2 | |
| SCHEMBL6764958 | 0.83 | KAT6A (0.52) | KAT6AGAALMNAKMT2A | |
| SCHEMBL6764909 | 0.83 | RAB9A (0.57) | GAAHTTMEN1MAPTKMT2A | |
| SCHEMBL6769558 | 0.81 | KMT2A (0.50) | GAAMEN1LMNAKMT2A | |
| SCHEMBL7109395 | 0.78 | RAB9A (0.56) | GAAMEN1LMNAMAPTKMT2A | |
| SCHEMBL20233293 | 0.75 | KAT6A (0.78) | KAT6AGAAHTTMEN1KMT2A | |
| SCHEMBL15482049 | 0.74 | CYP2C19 (0.59) | KAT6AGAAHTTMEN1LMNA | |
| SCHEMBL6761507 | 0.71 | ALDH1A1 (0.51) | HTTMEN1LMNAMAPTKMT2A | |
| SCHEMBL355627 | 0.70 | L3MBTL1 (0.67) | HTTMEN1LMNAKMT2A | |
| SCHEMBL5794551 | 0.70 | ALDH1A1 (0.51) | GAAHTTEGFRERBB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730704-B2 | REACTING AN ARYLOXYPROPIONIC ACID HYDRAZIDE WITH AN ARYLSULFONYL CHLORIDE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2004-05-04 | — | — | US | disclosed |
| US-20030187065-A1 | 1-(ARYLOXY)PROPIONOYL-2-ARYLSULFONYL HYDRAZINES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS HYPOGLYCEMIC AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187065-A1 | 1-(ARYLOXY)PROPIONOYL-2-ARYLSULFONYL HYDRAZINES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS HYPOGLYCEMIC AGENTS | IAPP, DPP4, GLP1R | KAT6A 4223/4885HTR1A 2441/4885HTR7 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.